中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果將就適應症提上市申請

阿斯達克財經

2024/12/18

中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合或不聯合鹽酸安羅替尼膠囊作為鞏固治療在同步/序貫放化療後未進展的、局部晚期/不可切除(III期)的非小細胞肺癌(NSCLC)患者中的III期臨牀研究(TQB2450-III-05)已完成方案預設的期中分析，獨立數據監查委員會(IDMC)判定主要研究終點無進展生存期(PFS)達到方案預設的優效界值。集團已與中國...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492972491"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492972491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492972491?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","is_english":false,"pubTime":"2024-12-18 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492972491","market":"other","top_or_hot":-1,"title":"中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果  將就適應症提上市申請","media":"阿斯達克財經","content":"<div>\n<p>中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合或不聯合鹽酸安羅替尼膠囊作為鞏固治療在同步/序貫放化療後未進展的、局部晚期/不可切除(III期)的非小細胞肺癌(NSCLC)患者中的III期臨牀研究(TQB2450-III-05)已完成方案預設的期中分析，獨立數據監查委員會(IDMC)判定主要研究終點無進展生存期(PFS)達到方案預設的優效界值。集團已與中國...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果  將就適應症提上市申請</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果  將就適應症提上市申請\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2024-12-18 17:05</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合或不聯合鹽酸安羅替尼膠囊作為鞏固治療在同步/序貫放化療後未進展的、局部晚期/不可切除(III期)的非小細胞肺癌(NSCLC)患者中的III期臨牀研究(TQB2450-III-05)已完成方案預設的期中分析，獨立數據監查委員會(IDMC)判定主要研究終點無進展生存期(PFS)達到方案預設的優效界值。集團已與中國...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"歐康維視生物-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN","article_id":"2492972491","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492972491","pubTimestamp":1734512700,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"集團已與中國國家藥品監督管理局藥品審評中心就該適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。同步/序貫放化療後未進展的、局部晚期/不可切除的NSCLC的鞏固治療是安羅替尼即將申報上市的第11個適應症、貝莫蘇拜單抗即將申報上市的第4個適應症。(港股報價延遲最少十五分鐘。沽空資料截至 2024-12-18 16:25。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1574":"生物医药B类股","01177":"中国生物制药"},"translate_title":"Sinopharmaceutical (01177. HK) Phase III study of non-small cell lung cancer consolidation therapy drugs after radiotherapy and chemotherapy achieved positive results and will submit a marketing application for indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"01477":1},"content_text":"中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合或不聯合鹽酸安羅替尼膠囊作為鞏固治療在同步/序貫放化療後未進展的、局部晚期/不可切除(III期)的非小細胞肺癌(NSCLC)患者中的III期臨牀研究(TQB2450-III-05)已完成方案預設的期中分析，獨立數據監查委員會(IDMC)判定主要研究終點無進展生存期(PFS)達到方案預設的優效界值。集團已與中國國家藥品監督管理局藥品審評中心(CDE)就該適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。同步/序貫放化療後未進展的、局部晚期/不可切除(III期)的NSCLC的鞏固治療是安羅替尼即將申報上市的第11個適應症、貝莫蘇拜單抗即將申報上市的第4個適應症。(sl/w)(港股報價延遲最少十五分鐘。沽空資料截至 2024-12-18 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}

中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果 將就適應症提上市申請

熱議股票

中生製藥(01177.HK)非小細胞肺癌放化療後鞏固治療藥物III期研究取得陽性結果將就適應症提上市申請